Dream Of FDA-CMS Parallel Review May Require New Tack, Suggests Gottlieb

If FDA and CMS want a parallel review process that's palatable to manufacturers, or even agency staffers, they will need to try a new tack, regulatory expert and former FDAer Scott Gottlieb suggests.